eligibility_summary
Eligible: adults (≥18) with relapsed/refractory CD22+ B‑cell ALL who started inotuzumab ozogamicin monotherapy between Feb 2017–Feb 2022, Ph+ cases must have failed ≥1 TKI. Exclude: patients who did not complete at least 1 InO cycle or received InO combined with chemotherapy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05597085 is a retrospective observational study of inotuzumab ozogamicin (InO, Besponsa/Inonza) monotherapy in adult relapsed/refractory B‑cell ALL, including Ph+ patients after ≥1 TKI failure. Drug/intervention and mechanism: InO is an antibody–drug conjugate (humanized anti‑CD22 monoclonal antibody linked to calicheamicin). It binds CD22 on B cells, is internalized, and releases calicheamicin to cause DNA double‑strand breaks and apoptosis. Cells/pathways targeted: CD22‑positive B‑lineage lymphoblasts, CD22-mediated endocytosis and downstream DNA‑damage/apoptotic pathways. Data sourced from Indian hospital EMRs.